*仅供医学专业人士阅读参考
*以下内容仅供医疗卫生专业人士浏览。
精彩资讯等你来
参考文献：
[1]. 王峰, 陈冬良, 王梓贤, 等. 不可切除的转移性结直肠癌患者接受姑息治疗的中国现状调查. 中华胃肠外科杂志, 2024, 27(7): 718-725.
[2]. Argiles G, Arnold D, Prager G, et al. Maximising clinical benefit with adequate patient management beyond the second line in mCRC. ESMO Open. 2019; 4(2): e000495.
[3]. Lv W, Liu B, Feng T, et al. A multi-cohort study of treatment regimens for metastatic colorectal cancer (mCRC) :Subgroup analysis of sequential therapy between Fruquintinib and Regorafenib.2025AACR CT085
[4]. Li J, Qin S, Xu RH, et al. Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer: The FRESCO Randomized Clinical Trial. JAMA. 2018;319(24):2486-2496.
[5]. Dasari A, Lonardi S, Garcia-Carbonero R, et al. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study. Lancet. 2023;402(10395):41-53.
[6]. Lonardi S, Dasari A, Tabernero J, et al. Overall survival with fruquintinib versus placebo after adjusting for subsequent anticancer therapy in patients with refractory metastatic colorectal cancer in the FRESCO-2 study. 2025 ASCO GI 171.
审批号：NP-AYT-25N332-Valid Until-2027-April
本资料由和黄医药提供支持
本资料旨在促进医药信息的沟通和交流，而非广告宣传。本资料内容不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议。若您想了解更多有关疾病知识的信息，请咨询医疗卫生专业人士。
* 此文仅用于向医学人士提供科学信息，不代表本平台观点
